Evidence Snapshot

CDK6/cyclin D1

CHEMBL2111455 PROTEIN COMPLEX Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:20Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:31 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2111455

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats CDK6/cyclin D1 as ChEMBL target CHEMBL2111455, mapped to UniProt P24385. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

CDK6/cyclin D1

PROTEIN COMPLEX · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2111455

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P24385

G1/S-specific cyclin-D1

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why CDK6/cyclin D1 matters

As of 2026-09-13

CDK6/cyclin D1 is reviewed as G1/S-specific cyclin-D1 (UniProt P24385); CDK6/cyclin D1 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 607 compounds, and 121 assays, with lead potency reaching pChEMBL 10.2.

Protein context

G1/S-specific cyclin-D1

G1/S-specific cyclin-D1 Sequence length is 295 aa.

Review this target as CDK6/cyclin D1, mapped to UniProt P24385. ChEMBL maps the protein component as G1/S-specific cyclin-D1. Sequence length is 295 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P24385 Protein

Disease context

breast cancer

CDK6/cyclin D1 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include PALBOCICLIB.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include PALBOCICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 1 linked drug

Activity base

Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 607 compounds, and 121 assays for this target. The dominant activity type is KI. CHEMBL5817327 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL5817327 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine

5 approved pChEMBL 10.2

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why CDK6/cyclin D1 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P24385, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why breast cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

607

Total Compounds

121

Total Assays

Approved Drugs

IC50: 333.0, KI: 641.0, KD: 2.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5817327	10.2	Ki	—
No preferred name CHEMBL5281860	10.2	Ki	—
No preferred name CHEMBL5994083	10.1	Ki	—
No preferred name CHEMBL4446357	10.1	Ki	Clinical
No preferred name CHEMBL5833205	10.0	Ki	—